Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.

In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.
PMID: 28736275 [PubMed - as supplied by publisher]

Source: Clinical Immunology - July 20, 2017 Category: Allergy & Immunology Authors: Alessandra S, Nicola T, Federica T, Giulia R, GianMaria F, Fabiola C, Marzia M, Raffaella L, Chiara T, Gianpiero D, Rita C, Veronica B, Eleonora C, Federico M, Chiara A Tags: Clin Immunol Source Type: research